BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,799 · see citing works

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,317 · see citing works

BRAF mutation in thyroid cancer

Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,293 · see citing works

BRAF and RAS mutations in human lung cancer and melanoma.

Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048 · see citing works

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Sebolt, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A. M., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A. J., Przybranowski, S. A., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 972 · see citing works

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750 · see citing works

Regulation of Raf-1 by direct feedback phosphorylation.

Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663 · see citing works

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Ohren, J. F., Chen, H., Pavlovsky, A. G., Whitehead, C. E., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. A., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 635 · see citing works

Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate

Santos, S. D. M., Verveer, P. J., & Bastiaens, P. I. H. (2007) · Nature Cell Biology · doi:10.1038/ncb1543 · Cited by 609 · see citing works

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578 · see citing works

Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization

Garnett, M. J., Rana, S., Paterson, H., Barford, D., & Marais, R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.022 · Cited by 416 · see citing works

Suppression of BRAF(V599E) in human melanoma abrogates transformation.

Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 408 · see citing works

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis

Porter, A. C., & Vaillancourt, R. R. (1998) · Oncogene · doi:10.1038/sj.onc.1202171 · Cited by 322 · see citing works

Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors

Sharma, A. K., Trivedi, N. R., Zimmerman, M., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 318 · see citing works

Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1

O’Neill, E. E., Rushworth, L. K., Baccarini, M., & Kölch, W. (2004) · Science · doi:10.1126/science.1103233 · Cited by 317 · see citing works

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism

Chen, J., Fujii, K., Zhang, L., Roberts, T. M., & Fu, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141224398 · Cited by 316 · see citing works

BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.

Wang, L., Cunningham, J. M., Winters, J. L., Guenther, J. C., French, A. J., Boardman, L. A., Burgart, L. J., McDonnell, S. K., Schaid, D. J., & Thibodeau, S. N. (2003) · PubMed · Cited by 280 · see citing works

Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation

Groß, I., Bassit, B., Benezra, M., & Licht, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108234200 · Cited by 252 · see citing works

K-ras as a target for cancer therapy

Friday, B. B., & Adjei, A. A. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.001 · Cited by 245 · see citing works

In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours

Sieben, N. L. G., Macropoulos, P., Roemen, G. M. J. M., Kolkman-Uljee, S. M., Fleuren, G. J., Houmadi, R., Diss, T. C., Warren, B. K., Al‐Adnani, M., de Goeij, A. F. P. M., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237 · see citing works

Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf

Yusoff, P., Lao, D.-H., Ong, S. H., Wong, E. S. M., Lim, J., Lo, T. L., Leong, H. F., Fong, C. W., & Guy, G. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108368200 · Cited by 229 · see citing works

Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models

Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J., Wong, L. L.-Y., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 228 · see citing works

Activation and Cellular Localization of the Cyclosporine A-sensitive Transcription Factor NF-AT in Skeletal Muscle Cells

Abbott, K. L., Friday, B. B., Thaloor, D., Murphy, T. J., & Pavlath, G. K. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.10.2905 · Cited by 226 · see citing works

BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma

Salvatore, G., Falco, V. D., Salerno, P., Nappi, T. C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R. M., Wilhelm, S. M., & Santoro, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2378 · Cited by 171 · see citing works

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma

Huynh, H. T., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150 · see citing works

Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

Brown, A. P., Carlson, T., Loi, C., & Graziano, M. J. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0323-5 · Cited by 127 · see citing works

SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant

Tsavachidou, D., Coleman, M. L., Athanasiadis, G., Li, S., Licht, J. D., Olson, M. F., & Weber, B. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1669 · Cited by 118 · see citing works

Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf

Brummer, T., Naegele, H., Reth, M. G., & Misawa, Y. (2003) · Oncogene · doi:10.1038/sj.onc.1207185 · Cited by 115 · see citing works

ERK Pathway Positively Regulates the Expression of Sprouty Genes

Ozaki, K., Kadomoto, R., Asato, K., Tanimura, S., Itoh, N., & Kohno, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5295 · Cited by 113 · see citing works

Signaling Through RAS-RAF-MEK-ERK: from Basics to Bedside

Zebisch, A., Czernilofsky, A. P., Kéri, G., Smigelskaite, J., Sill, H., & Troppmair, J. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780059670 · Cited by 112 · see citing works

Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244

Ball, D. W., Jin, N. Y., Rosen, D. M., Dackiw, A. P. B., Sidransky, D., Xing, M., & Nelkin, B. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1184 · Cited by 109 · see citing works

Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)

Sapio, M. R., Posca, D., Troncone, G., Pettinato, G., Palombini, L., Rossi, G., Fenzi, G., & Vitale, M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02072 · Cited by 102 · see citing works

Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants

Brognard, J., & Dennis, P. A. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401054 · Cited by 89 · see citing works

Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene

Valenzuela, D., & Groffen, J. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.2.843 · Cited by 86 · see citing works

Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors

McIntyre, A., Summersgill, B. M., Spendlove, H. E., Huddart, R. A., Houlston, R. S., & SHIPLEY, J. M. (2005) · Neoplasia · doi:10.1593/neo.05514 · Cited by 78 · see citing works

Identification of the Anti-proliferative Protein Tob as a MAPK Substrate

Maekawa, M., Nishida, E., & Tanoue, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204506200 · Cited by 77 · see citing works

Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene.

Ledwith, B. J., Manam, S., Kraynak, A. R., Nichols, W. W., & Bradley, M. O. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.4.1545 · Cited by 76 · see citing works

Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352

Delaney, A. M., Printen, J. A., Chen, H., Fauman, E. B., & Dudley, D. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.21.7593-7602.2002 · Cited by 75 · see citing works

Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy

Wallace, E. M., Lyssikatos, J. P., Yeh, T. C., Winkler, J. D., & Koch, K. M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507723 · Cited by 70 · see citing works

Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro

Meng, X. W., Chandra, J., Loegering, D. A., Becelaere, K. V., Kottke, T. J., Gore, S. D., Karp, J. E., Sebolt-Leopold, J., & Kaufmann, S. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304793200 · Cited by 53 · see citing works

Ras as a target in cancer therapy

Midgley, R. S., & Kerr, R. S. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00189-5 · Cited by 45 · see citing works

Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126

Eppstein, A. C., Sandoval, J. A., Klein, P. J., Woodruff, H. A., Grosfeld, J. L., Hickey, R. J., Malkas, L. H., & Schmidt, C. M. (2006) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2005.10.047 · Cited by 22 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888 · see citing works

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · see citing works

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 587 · see citing works

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling

Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535 · see citing works

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482 · see citing works

PTEN: Multiple Functions in Human Malignant Tumors

Milella, M., Falcone, I., Conciatori, F., Incani, U. C., Curatolo, A. D., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 469 · see citing works

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 446 · see citing works

The clinical development of MEK inhibitors

Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 403 · see citing works

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 317 · see citing works

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Faber, A. C., Li, D., Song, Y., Liang, M., Yeap, B. Y., Bronson, R. T., Lifshits, E., Zhao, C., Maira, S.-M., Garcı́a-Echeverrı́a, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 315 · see citing works

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J. A., Larkin, J., Hersey, P., Middleton, M. R., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 276 · see citing works

Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032

Søndergaard, J. N., Nazarian, R., Wang, Q., Guo, D., Hsueh, T., Mok, S., Sazegar, H., MacConaill, L. E., Barretina, J., Kehoe, S. M., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-39 · Cited by 225 · see citing works

Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 211 · see citing works

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

Chen, X., Wu, Q., Tan, L., PORTER, D. A., Jager, M. J., Emery, C., & Bastian, B. C. (2013) · Oncogene · doi:10.1038/onc.2013.418 · Cited by 209 · see citing works

Strong negative feedback from Erk to Raf confers robustness to MAPK signalling

Fritsche‐Guenther, R., Witzel, F., Sieber, A., Herr, R., Schmidt, N., Braun, S. L., Brummer, T., Sers, C., & Blüthgen, N. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.27 · Cited by 193 · see citing works

Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib

Stegmeier, F. P., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 192 · see citing works

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183 · see citing works

Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial

Matei, D. E., Sill, M. W., Lankes, H. A., DeGeest, K., Bristow, R. E., Mutch, D. G., Yamada, S. D., Cohn, D. E., Calvert, V. S., Farley, J. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7856 · Cited by 175 · see citing works

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 161 · see citing works

Network quantification of EGFR signaling unveils potential for targeted combination therapy

Klinger, B., Sieber, A., Fritsche‐Guenther, R., Witzel, F., Berry, L., Schumacher, D., Yan, Y., Durek, P., Merchant, M. A., Schäfer, R., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.29 · Cited by 154 · see citing works

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

Meng, J., Dai, B., Fang, B., Bekele, B. N., Bornmann, W. G., Sun, D., Peng, Z., Herbst, R. S., Papadimitrakopoulou, V. A., Minna, J. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014124 · Cited by 146 · see citing works

BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications

Tang, K., & Lee, C. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70025-3 · Cited by 141 · see citing works

MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms

Wu, P.-K., & Park, J.-I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.023 · Cited by 132 · see citing works

Targeting the RAS oncogene

Takashima, A., & Faller, D. V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.764990 · Cited by 135 · see citing works

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets

Knauf, J. A., & Fagin, J. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.013 · Cited by 131 · see citing works

Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E. G., Galvin, K. M., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 125 · see citing works

Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding

Agyeman, A., Jha, B. K., Mazumdar, T., & Houghton, J. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2046 · Cited by 126 · see citing works

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 116 · see citing works

MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

Jiang, C. C., Lai, F., Thorne, R. F., Yang, F., Liu, H., Hersey, P., & Zhang, X. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2225 · Cited by 117 · see citing works

Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

Ciuffreda, L., Bufalo, D. D., Desideri, M., Sanza, C. D., Stoppacciaro, A., Ricciardi, M. R., Chiaretti, S., Tavolaro, S., Benassi, B., Bellacosa, A., et al. (2009) · Neoplasia · doi:10.1593/neo.09398 · Cited by 112 · see citing works

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

Ambrosini, G., Pratilas, C. A., Qin, L., Tadi, M., Surriga, O., Carvajal, R. D., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3086 · Cited by 110 · see citing works

Efficient synthesis of phycocyanobilin in mammalian cells for optogenetic control of cell signaling

Uda, Y., Goto, Y., Oda, S., Kohchi, T., Matsuda, M., & Aoki, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707190114 · Cited by 109 · see citing works

Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling

Kidger, A. M., Rushworth, L. K., Stellzig, J., Davidson, J., Bryant, C., Bayley, C., Caddye, E., Rogers, T., Keyse, S. M., & Caunt, C. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614684114 · Cited by 98 · see citing works

Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy

Gazdar, A. F. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9201-z · Cited by 91 · see citing works

Targeting drivers of melanoma with synthetic small molecules and phytochemicals

Strickland, L. R., Pal, H. C., Elmets, C. A., & Afaq, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.016 · Cited by 81 · see citing works

Feedback regulation in cell signalling: Lessons for cancer therapeutics

Nguyen, L. K., & Kholodenko, B. Ν. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.024 · Cited by 73 · see citing works

Novel Designs and End Points for Phase II Clinical Trials

Adjei, A. A., Christian, M. C., & Ivy, P. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2035 · Cited by 76 · see citing works

Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression

Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 76 · see citing works

NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells

Küper, C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00293 · Cited by 75 · see citing works

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

Annunziata, C. M., Hernandez, L. F., Davis, R. E., Zingone, A., Lamy, L., Lam, L. T., Hurt, E. M., Shaffer, A. L., Kuehl, W. M., & Staudt, L. M. (2010) · Blood · doi:10.1182/blood-2010-04-278788 · Cited by 74 · see citing works

Inducible Pluripotent Stem Cell–Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1 -Associated Noonan Syndrome

Jaffré, F., Miller, C. L., Schänzer, A., Evans, T., Roberts, A. E., Hahn, A., & Kontaridis, M. I. (2019) · Circulation · doi:10.1161/circulationaha.118.037227 · Cited by 73 · see citing works

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Yoon, Y., Kim, H., Han, S., Hur, H.-S., Oh, D. Y., Im, S., Bang, Y., & Kim, T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0300 · Cited by 71 · see citing works

Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells

Muralidharan-Chari, V., Kohan, H. G., Asimakopoulos, A. G., Sudha, T., Sell, S., Kannan, K., Boroujerdi, M., Davis, P. J., & Mousa, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10395 · Cited by 71 · see citing works

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Berlak, M., Tucker, E. R., Dorel, M., Winkler, A., McGearey, A., Rodríguez-Fos, E., Costa, B. M. D., Barker, K. T., Fyle, E., Calton, E. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01583-z · Cited by 64 · see citing works

An immediate–late gene expression module decodes ERK signal duration

Uhlitz, F., Sieber, A., Wyler, E., Fritsche‐Guenther, R., Meisig, J., Landthaler, M., Klinger, B., & Blüthgen, N. (2017) · Molecular Systems Biology · doi:10.15252/msb.20177554 · Cited by 64 · see citing works

Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines

Garon, E. B., Finn, R. S., Hosmer, W., Dering, J., Ginther, C., Adhami, S., Kamranpour, N., Pitts, S. L., Desai, A. J., Elashoff, D. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0037 · Cited by 63 · see citing works

Emerging MEK inhibitors

McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63 · see citing works

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J. D., Chresta, C. M., Smith, P. D., Fang, B., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9844 · Cited by 62 · see citing works

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2

Yoshida, T., Kakegawa, J., Yamaguchi, T., Hantani, Y., Okajima, N., Sakai, T., Watanabe, Y., & Nakamura, M. (2012) · Oncotarget · doi:10.18632/oncotarget.747 · Cited by 62 · see citing works

Targeting Oncogenic BRAF in Human Cancer

Pratilas, C. A., Xing, F., & Solit, D. B. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2011_162 · Cited by 60 · see citing works

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0145 · Cited by 57 · see citing works

Current status and future direction in the management of malignant melanoma

Gladfelter, P., Darwish, N. H. E., & Mousa, S. A. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000379 · Cited by 55 · see citing works

Oncogenic <i>Kras</i> Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17

Van Schaeybroeck, S., Kyula, J. N., Fenton, A., Fenning, C. S., Sasazuki, T., Shirasawa, S., Longley, D. B., & Johnston, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0714 · Cited by 51 · see citing works

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 57 · see citing works

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113217 · Cited by 50 · see citing works

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

James, J., Ruggeri, B. R., Armstrong, R. C., Rowbottom, M. W., Jones‐Bolin, S., Gunawardane, R. N., Dobrzański, P., Gardner, M. F., Zhao, H. Q., Cramer, M. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0645 · Cited by 50 · see citing works

Role of B-RafV600E in differentiated thyroid cancer and preclinical validation of compounds against B-RafV600E

Nucera, C., Goldfarb, M. R., Hodin, R. A., & Parangi, S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.01.003 · Cited by 50 · see citing works

MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells

Miniotis, M. F., Arunan, V., Eykyn, T. R., Marais, R., Workman, P., Leach, M. O., & Beloueche‐Babari, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1969 · Cited by 49 · see citing works

Systems Pharmacology

Boran, A. D. W., & Iyengar, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20191 · Cited by 49 · see citing works

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 49 · see citing works

Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma

Wu, S., & Singh, R. K. (2011) · Current Molecular Medicine · doi:10.2174/156652411800615153 · Cited by 47 · see citing works

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

Morelli, M. P., Tentler, J. J., Kulikowski, G. N., Tan, A. C., Bradshaw‐Pierce, E. L., Pitts, T. M., Brown, A. M., Nallapareddy, S., Arcaroli, J. J., Serkova, N. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1507 · Cited by 47 · see citing works

The Biology and Clinical Development of MEK Inhibitors for Cancer

Luke, J., Ott, P., & Shapiro, G. (2014) · Drugs · doi:10.1007/s40265-014-0315-4 · Cited by 38 · see citing works

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

Ricciardi, M. R., Scerpa, M. C., Bergamo, P., Ciuffreda, L., Petrucci, M. T., Chiaretti, S., Tavolaro, S., Mascolo, M. G., Abrams, S. L., Steelman, L. S., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0886-z · Cited by 43 · see citing works

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors

Stones, C. J., Kim, J. E., Joseph, W. R., Leung, E. Y., Marshall, E. S., Finlay, G. J., Shelling, A. N., & Baguley, B. C. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00066 · Cited by 43 · see citing works

Specifically targeting ERK1 or ERK2 kills Melanoma cells

Qin, J., Xin, H., & Nickoloff, B. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-15 · Cited by 43 · see citing works

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells

Komatsu, N., Fujita, Y., Matsuda, M., & Aoki, K. (2015) · Oncogene · doi:10.1038/onc.2015.16 · Cited by 39 · see citing works

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 40 · see citing works

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

Curatolo, A. D., Conciatori, F., Incani, U. C., Bazzichetto, C., Falcone, I., Corbo, V., D’Agosto, S. L., Eramo, A., Sette, G., Sperduti, I., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0820-5 · Cited by 36 · see citing works

Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy

El-Hachem, N., Gendoo, D. M. A., Ghoraie, L. S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Fang, A., Birkwood, E., Ho, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0096 · Cited by 35 · see citing works

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33 · see citing works

Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer

Liu, S., Zou, Q., Chen, J., Yao, X., Guan, P., Liang, W., Deng, P., Lai, X., Yin, J., Chen, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145035 · Cited by 34 · see citing works

Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells

Nishioka, C., Ikezoe, T., Yang, J., & Yokoyama, A. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0372-4 · Cited by 34 · see citing works

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

Munck, J. M., Berdini, V., Bevan, L., Brothwood, J. L., Castro, J., Courtin, A., East, C., Ferraldeschi, R., Heightman, T. D., Hindley, C. J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0909 · Cited by 33 · see citing works

Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems

Nagaria, T. S., Shi, C., Leduc, C., Hoskin, V., Sikdar, S., Sangrar, W., & Greer, P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.20534 · Cited by 32 · see citing works

The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway

Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32 · see citing works

Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

Daouti, S., Wang, H., Li, W., Higgins, B., Kolinsky, K. D., Packman, K. E., Specian, A., Kong, N., Huby, N. J. S., Yang, W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2627 · Cited by 32 · see citing works

Modelling signalling networks from perturbation data

Dorel, M., Klinger, B., Groß, T., Sieber, A., Prahallad, A., Bosdriesz, E., Wessels, L. F. A., & Blüthgen, N. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty473 · Cited by 31 · see citing works

Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1

Nishioka, C., Ikezoe, T., Yang, J., & Yokoyama, A. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0483-y · Cited by 30 · see citing works

Robustness of signal transduction pathways

Blüthgen, N., & Legewie, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1162-7 · Cited by 30 · see citing works

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors

Honda, K., Yamamoto, N., Nokihara, H., Tamura, Y., Asahina, H., Yamada, Y., Suzuki, S., Yamazaki, N., Ogita, Y., & Tamura, T. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2228-4 · Cited by 29 · see citing works

Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as potential B-Raf inhibitors

Yang, Y., Yang, B., Zou, Y., Li, G., & Zhu, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.012 · Cited by 29 · see citing works

Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2

Kidger, A. M., Munck, J. M., Saini, H. K., Balmanno, K., Minihane, E., Courtin, A., Graham, B. L., O’Reilly, M., Odle, R., & Cook, S. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0505 · Cited by 29 · see citing works

Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition

Schweppe, R. E., Kerege, A. A., Sharma, V., Poczobutt, J. M., Gutierrez‐Hartmann, A., Grzywa, R. L., & Haugen, B. R. (2009) · Thyroid · doi:10.1089/thy.2008.0362 · Cited by 28 · see citing works

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244

Ammoun, S., Ristic, N., Matthies, C., Hilton, D. A., & Hanemann, C. O. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.017 · Cited by 27 · see citing works

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer

Sale, M. J., & Cook, S. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140129 · Cited by 25 · see citing works

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Flemington, V., Davies, E. J., Robinson, D. M., Sandin, L. C., Delpuech, O., Zhang, P., Hanson, L. L., Farrington, P. M., Bell, S., Falenta, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0002 · Cited by 26 · see citing works

Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy

Yu, C., Zhang, M., Song, J., Zheng, X., Xu, G., Bao, Y., Lan, J., Luo, D., Hu, J., Li, J. J., et al. (2020) · Molecular Biomedicine · doi:10.1186/s43556-020-00013-0 · Cited by 26 · see citing works

Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs

Fujita, Y., Komatsu, N., Matsuda, M., & Aoki, K. (2014) · FEBS Journal · doi:10.1111/febs.12852 · Cited by 25 · see citing works

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

Shukla, A., Rai, K., Shukla, V., Chaturvedi, N. K., Bociek, R. G., Pirruccello, S. J., Band, H., Lu, R., & Joshi, S. S. (2016) · Blood · doi:10.1182/blood-2015-09-669317 · Cited by 24 · see citing works

Inhibition of metadherin sensitizes breast cancer cells to AZD6244

Kong, X., Moran, M. S., Zhao, Y., & Yang, Q. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18868 · Cited by 23 · see citing works

Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects

Smith, K. P., Gifford, K. M., Waitzman, J. S., & Rice, S. E. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24605 · Cited by 23 · see citing works

Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors

Duffy, A. G., & Kummar, S. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0125-x · Cited by 22 · see citing works

Vascular-targeted agents for the treatment of angiosarcoma

Young, R., Woll, P. J., Staton, C. A., Reed, M., & Brown, N. J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2345-0 · Cited by 22 · see citing works

Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.

King, J., & Nathan, P. (2014) · Future Oncology · doi:10.2217/fon.14.89 · Cited by 23 · see citing works

Challenges in developing targeted therapy for pancreatic adenocarcinoma

Mahalingam, D., & Giles, F. J. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1389 · Cited by 20 · see citing works

MEK inhibitors beyond monotherapy: current and future development.

Templeton, I. E., & Musib, L. (2015) · Current opinion in pharmacology (Print) · doi:10.1016/j.coph.2015.05.012 · Cited by 20 · see citing works

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf- Mutant Human Cutaneous Melanoma Cells

Gopal, Y. N. V., Deng, W., Woodman, S. E., Komurov, K., Ram, P. T., Smith, P. D., & Davies, M. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0902 · Cited by 225 · see citing works

Abstract A71: Basal- and treatment-induced activation of the PI3K-AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY-142886) in melanoma

Nanda, V. G. Y., Deng, W., Smith, P. D., & Davies, M. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-a71

Biologically driven interpretation reveals molecular signatures predictive of oncogenic addiction to MEK signaling and cell line response to the MEK1/2 inhibitor AZD6244 (ARRY-142886)

Dry, J. R., Harbron, C. G., Hickinson, M. D., Graham, A., French, T., Chang, K., Cassidy, A., Beran, G. J., Cockerill, M. J., Chresta, C. M., et al. (2008) · Cancer Research · Cited by 1 · see citing works

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative

Kinase, S.-R., Proteins, R., Friday, B. B., Yu, C., Dy, G. K., Al, E., Aacr, C. T., Signal-regulated, F. B. E., Proteins, R., Friday, B. B., et al. (2013)

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Davies, B. R., Logié, A., McKay, J. S., Martin, P. D., Steele, S. J., Jenkins, R., Cockerill, M. J., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 388 · see citing works